CN102391356A - D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 - Google Patents
D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 Download PDFInfo
- Publication number
- CN102391356A CN102391356A CN2011102795086A CN201110279508A CN102391356A CN 102391356 A CN102391356 A CN 102391356A CN 2011102795086 A CN2011102795086 A CN 2011102795086A CN 201110279508 A CN201110279508 A CN 201110279508A CN 102391356 A CN102391356 A CN 102391356A
- Authority
- CN
- China
- Prior art keywords
- ring
- compound
- preparation
- analogue
- dihydropyrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 150000003431 steroids Chemical class 0.000 title abstract 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 27
- 230000003647 oxidation Effects 0.000 claims abstract description 6
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 229930182470 glycoside Natural products 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 230000003637 steroidlike Effects 0.000 claims description 23
- 238000004821 distillation Methods 0.000 claims description 19
- -1 benzyl amino, amino Chemical group 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000012074 organic phase Substances 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 150000001263 acyl chlorides Chemical class 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 4
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 claims description 3
- UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 claims description 3
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 238000012805 post-processing Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 claims description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 2
- NUZMPIYYRKIQCG-UHFFFAOYSA-N C(=O)O.I(=O)(=O)C1=CC=CC=C1 Chemical group C(=O)O.I(=O)(=O)C1=CC=CC=C1 NUZMPIYYRKIQCG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 2
- 150000002978 peroxides Chemical class 0.000 claims description 2
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 abstract description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000005858 glycosidation reaction Methods 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 206010029260 Neuroblastoma Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000002777 nucleoside Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 125000003147 glycosyl group Chemical group 0.000 description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 description 11
- 239000011734 sodium Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 125000006414 CCl Chemical group ClC* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- PIOZZBNFRIZETM-UHFFFAOYSA-L magnesium;2-carbonoperoxoylbenzoic acid;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].OOC(=O)C1=CC=CC=C1C([O-])=O.OOC(=O)C1=CC=CC=C1C([O-])=O PIOZZBNFRIZETM-UHFFFAOYSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- GFRQBEMRUYIKAQ-WDSKDSINSA-N 1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-iodopyrimidine-2,4-dione Chemical compound O1[C@@H](CO)OC[C@H]1N1C(=O)NC(=O)C(I)=C1 GFRQBEMRUYIKAQ-WDSKDSINSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002718 pyrimidine nucleoside Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110279508 CN102391356B (zh) | 2011-09-20 | 2011-09-20 | D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110279508 CN102391356B (zh) | 2011-09-20 | 2011-09-20 | D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102391356A true CN102391356A (zh) | 2012-03-28 |
CN102391356B CN102391356B (zh) | 2013-05-01 |
Family
ID=45858757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110279508 Active CN102391356B (zh) | 2011-09-20 | 2011-09-20 | D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102391356B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103193851A (zh) * | 2013-04-07 | 2013-07-10 | 郑州大学 | 甾体二烯酰胺类化合物、其制备方法及其应用 |
CN107236016A (zh) * | 2017-07-14 | 2017-10-10 | 郑州大学 | 一种含1,2,3‑三氮唑的甾体嘌呤核苷类似物及其制备方法和应用 |
CN108358927A (zh) * | 2018-01-26 | 2018-08-03 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
-
2011
- 2011-09-20 CN CN 201110279508 patent/CN102391356B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
Non-Patent Citations (1)
Title |
---|
LI-HUAHUANG ET AL.: "Novel4-azasteroidal N-glycosideanaloguesbearingsugar-likeDring:Synthesisandanticanceractivities", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103193851A (zh) * | 2013-04-07 | 2013-07-10 | 郑州大学 | 甾体二烯酰胺类化合物、其制备方法及其应用 |
CN107236016A (zh) * | 2017-07-14 | 2017-10-10 | 郑州大学 | 一种含1,2,3‑三氮唑的甾体嘌呤核苷类似物及其制备方法和应用 |
CN108358927A (zh) * | 2018-01-26 | 2018-08-03 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
CN108358927B (zh) * | 2018-01-26 | 2020-09-01 | 郑州大学 | 1,4-二取代1,2,3-三氮唑核苷类似物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102391356B (zh) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103193858B (zh) | 螺甾碱烷型糖苷生物碱的合成方法 | |
CN110483608B (zh) | 沙蟾毒精衍生物及其制备方法、包含该衍生物的组合物、及其用途 | |
CN102250189A (zh) | 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途 | |
Huang et al. | Novel 4-azasteroidal N-glycoside analogues bearing sugar-like D ring: synthesis and anticancer activities | |
CN102127142A (zh) | 救必应酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN102391356B (zh) | D环为二氢吡喃环的甾体氮苷类似物及其制备、应用 | |
KR102394934B1 (ko) | Akt 억제제로서의 염 형태 및 이의 결정 형태 | |
CN103288913B (zh) | 一种新化合物、其药物组合物、其制备方法及其用途 | |
CN102391352B (zh) | 救必应酸氨基酸衍生物及其在制备抗肿瘤的药物中的应用 | |
Hrdlicka et al. | Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3′-C-ethynyluridine (EUrd) and 3′-C-ethynylcytidine (ECyd) | |
Zhou et al. | Design, synthesis and anti-tumor activities of carbamate derivatives of cinobufagin | |
CN106046105A (zh) | 一种甘草次酸、阿魏酸和硒代蛋氨酸三元化合物的制备方法及应用 | |
Yoo et al. | Synthesis of 2-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agents | |
CN104829619A (zh) | 一种取代芳基苦参碱类化合物及其制备方法与应用 | |
CN103232520A (zh) | 一种螺甾类化合物、其制备方法及医药用途 | |
CN114874281A (zh) | 一种齐墩果酸衍生物及其制备方法与应用 | |
CN109705189B (zh) | 具有式i所示结构的三萜衍生物及其制备方法和应用 | |
Ibrahim-Ouali et al. | Recent syntheses of steroid derivatives using the CuAAC “click” reaction | |
CN104672294B (zh) | 化合物3‑o‑(2‑(5‑氟尿嘧啶‑1‑)乙酰)‑熊果酸甲酯的合成及其作为抗肿瘤药物的应用 | |
Samunuri et al. | Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin | |
CN111533700B (zh) | 一种5-取代的尿嘧啶衍生物及其制备方法和应用 | |
Liu et al. | Synthesis and biological evaluation of ambradiolic acid as an inhibitor of glycogen phosphorylase | |
CN113956323B (zh) | 一种四环三萜衍生物及其制备方法和应用 | |
CN110804084B (zh) | 一种季鏻盐类薯蓣皂苷元衍生物及其合成方法和应用 | |
ES2700901A2 (es) | Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PHARMARON (BEIJING) CO., LTD. Free format text: FORMER OWNER: ZHENGZHOU UNIVERSITY Effective date: 20150508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 450001 ZHENGZHOU, HENAN PROVINCE TO: 100176 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150508 Address after: 100176 No. 6 Tai Tay Road, Beijing economic and Technological Development Zone Patentee after: Kanglong chemical (Beijing) new drug Technology Co., Ltd. Address before: 450001 Zhengzhou science and Technology Development Zone, Henan, No. 100 science Avenue Patentee before: Zhengzhou University |
|
CP01 | Change in the name or title of a patent holder |
Address after: No. 6 Thailand Road, Beijing economic and Technological Development Zone, Beijing Patentee after: Kanglong (Beijing) new drug technology Limited by Share Ltd Address before: No. 6 Thailand Road, Beijing economic and Technological Development Zone, Beijing Patentee before: Kanglong chemical (Beijing) new drug Technology Co., Ltd. |